Zevra Therapeutics Inc’s recently made public that its Director Bode John B acquired Company’s shares for reported $79624.0 on Mar 19 ’25. In the deal valued at $7.96 per share,10,000 shares were bought. As a result of this transaction, Bode John B now holds 40,000 shares worth roughly $0.32 million.
Then, Sangiovanni Timothy J. sold 3,000 shares, generating $23,588 in total proceeds. Upon selling the shares at $7.86, the SVP, Finance & Corp Controller now owns 16,341 shares.
Before that, Schafer Joshua sold 10,500 shares. Zevra Therapeutics Inc shares valued at $82,527 were divested by the CCO & EVP, Bus. Development at a price of $7.86 per share. As a result of the transaction, Schafer Joshua now holds 29,486 shares, worth roughly $0.24 million.
A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Maxim Group also remained covering ZVRA and reiterated its “Buy” recommendation on September 24, 2024. JMP Securities started covering the stock on September 24, 2024. It rated ZVRA as “a Mkt outperform”.
Price Performance Review of ZVRA
On Friday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock unchanged to $8.01. Over the last five days, the stock has lost -3.61%. Zevra Therapeutics Inc shares have fallen nearly -3.96% since the year began. Nevertheless, the stocks have risen 34.40% over the past one year. While a 52-week high of $9.76 was reached on 01/03/25, a 52-week low of $4.20 was recorded on 03/04/25. SMA at 50 days reached $7.91, while 200 days put it at $7.46.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 7.87, which if violated will result in even more drops to 7.73. On the upside, there is a resistance level at 8.15. A further resistance level may holdings at 8.28. The Relative Strength Index (RSI) on the 14-day chart is 51.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 37.50%. Stochastics %K at 60.94% indicates the stock is a holding.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-02-28, growing by 90046.0 shares to a total of 5.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 5.52 million shares. There was a rise of 1.6%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 02, 2024 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $18.
